3 papers
Retatrutide (LY3437943)
A novel triple agonist at GLP-1, GIP, and glucagon receptors. Recent landmark trials demonstrate substantial effects on body weight and glycemic control in humans.
Jastreboff AM, Kaplan LM, Frías JP, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
N Engl J Med · 2023 · 389(6):514–526
PubMed PMID 37366315Rosenstock J, Frias J, Jastreboff AM, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet · 2023 · 402(10401):529–544
PubMed PMID 37385280Coskun T, Urva S, Roell WC, et al.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Cell Metab · 2022 · 34(9):1234–1247.e9
PubMed PMID 35985340